Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
CytomX Therapeutics announces employment inducement grants » 08:15
09/16/21
09/16
08:15
09/16/21
08:15
CTMX

CytomX Therapeutics

$4.97 /

-0.03 (-0.60%)

CytomX Therapeutics…

CytomX Therapeutics announced that on September 15, 2021, the Company granted nine new employees options to purchase a total of 157,200 shares of the Company's common stock at an exercise price per share equal to $4.97, which was the closing trading price on September 15, 2021, the date of the grant. The stock options were granted pursuant to the Company's 2019 Employment Inducement Incentive Plan, which was approved by the Company's board of directors in August 2020 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

ShowHide Related Items >><<
CTMX CytomX Therapeutics
$4.97 /

-0.03 (-0.60%)

CTMX CytomX Therapeutics
$4.97 /

-0.03 (-0.60%)

05/28/21 Barclays
CytomX Therapeutics downgraded to Underweight from Equal Weight at Barclays
03/29/21
Fly Intel: Top five analyst initiations
03/29/21 JPMorgan
CytomX Therapeutics initiated with an Overweight at JPMorgan
03/23/21 Jefferies
CytomX Therapeutics upgraded to Buy from Hold at Jefferies
CTMX CytomX Therapeutics
$4.97 /

-0.03 (-0.60%)

  • 21
    Jan
Over a month ago
Hot Stocks
CytomX Therapeutics announces employment inducement grants » 08:14
08/17/21
08/17
08:14
08/17/21
08:14
CTMX

CytomX Therapeutics

$4.81 /

-0.035 (-0.72%)

CytomX Therapeutics…

CytomX Therapeutics announced that on August 16, 2021, the Company granted seven new employees options to purchase a total of 172,600 shares of the Company's common stock at an exercise price per share equal to $4.81, which was the closing trading price on August 16, 2021, the date of the grant.

ShowHide Related Items >><<
CTMX CytomX Therapeutics
$4.81 /

-0.035 (-0.72%)

CTMX CytomX Therapeutics
$4.81 /

-0.035 (-0.72%)

05/28/21 Barclays
CytomX Therapeutics downgraded to Underweight from Equal Weight at Barclays
03/29/21
Fly Intel: Top five analyst initiations
03/29/21 JPMorgan
CytomX Therapeutics initiated with an Overweight at JPMorgan
03/23/21 Jefferies
CytomX Therapeutics upgraded to Buy from Hold at Jefferies
CTMX CytomX Therapeutics
$4.81 /

-0.035 (-0.72%)

  • 21
    Jan
Syndicate
CytomX Therapeutics files $250M mixed securities shelf  07:13
08/17/21
08/17
07:13
08/17/21
07:13
CTMX

CytomX Therapeutics

$4.81 /

-0.035 (-0.72%)

 
ShowHide Related Items >><<
CTMX CytomX Therapeutics
$4.81 /

-0.035 (-0.72%)

CTMX CytomX Therapeutics
$4.81 /

-0.035 (-0.72%)

05/28/21 Barclays
CytomX Therapeutics downgraded to Underweight from Equal Weight at Barclays
03/29/21
Fly Intel: Top five analyst initiations
03/29/21 JPMorgan
CytomX Therapeutics initiated with an Overweight at JPMorgan
03/23/21 Jefferies
CytomX Therapeutics upgraded to Buy from Hold at Jefferies
CTMX CytomX Therapeutics
$4.81 /

-0.035 (-0.72%)

  • 21
    Jan
Earnings
CytomX Therapeutics reports Q2 EPS (30c), consensus (32c) » 16:53
08/05/21
08/05
16:53
08/05/21
16:53
CTMX

CytomX Therapeutics

$5.77 /

+0.21 (+3.78%)

Reports Q2 revenue $16M,…

Reports Q2 revenue $16M, consensus $16.86M. Cash, cash equivalents and short- and long-term investments totaled $366M as of June 30, 2021, compared to $316M as of December 31, 2020. "In the second quarter of 2021, we continued to advance our broad pipeline of Probody therapeutics across multiple modalities and cancer types. Our Phase 2 studies, evaluating our two lead conditionally activated antibody-drug conjugates, praluzatamab ravtansine, targeting CD166, and CX-2029, targeting CD71, are ongoing," said Sean McCarthy, CEO of CytomX Therapeutics. "The breadth of our progress and depth of our science have been highlighted by five clinical and scientific publications in peer-reviewed journals in 2021 to date, including a landmark preclinical publication demonstrating the power of Probody technology to increase the therapeutic window of an immune agonist."

ShowHide Related Items >><<
CTMX CytomX Therapeutics
$5.77 /

+0.21 (+3.78%)

CTMX CytomX Therapeutics
$5.77 /

+0.21 (+3.78%)

05/28/21 Barclays
CytomX Therapeutics downgraded to Underweight from Equal Weight at Barclays
03/29/21
Fly Intel: Top five analyst initiations
03/29/21 JPMorgan
CytomX Therapeutics initiated with an Overweight at JPMorgan
03/23/21 Jefferies
CytomX Therapeutics upgraded to Buy from Hold at Jefferies
CTMX CytomX Therapeutics
$5.77 /

+0.21 (+3.78%)

  • 21
    Jan
Hot Stocks
CytomX Therapeutics announces three publications on pacmilimab » 08:21
08/04/21
08/04
08:21
08/04/21
08:21
CTMX

CytomX Therapeutics

$5.73 /

+0.15 (+2.69%)

CytomX Therapeutics…

CytomX Therapeutics announced the publication of three articles in peer-reviewed journals on pacmilimab), the company's wholly-owned conditionally activated antibody directed against PD-L1 currently being developed in combination with praluzatamab ravtansine for the treatment of triple-negative breast cancer. "First-in-human PET Imaging Study of Pacmilimab Biodistribution Published in Clinical Cancer Research." To evaluate the effect of Probody modifications on biodistribution and pharmacokinetics, the company studied the biodistribution of pacmilimab labeled with the positron emission tomography isotope, zirconium-89, in patients with locally advanced or metastatic malignancies. 89Zr-labeled pacmilimab was found to be intact in the blood for up to 7 days and predominantly in its masked form in circulation, consistent with Probody design. All patients showed uptake of radioactivity into tumor lesions. Tumor-to-blood ratio of radioactivity increased over time, indicating that tumor uptake of pacmilimab is specific and retained in the tumor. "First-in-human Study of Pacmilimab in Patients with Advanced Solid Tumors Published in the Journal for ImmunoTherapy of Cancer." Combining all patients treated at 10 mg/kg, the overall objective response rate in 114 evaluable patients who had at least one post-baseline disease assessment was 12 percent, with a disease control rate of 42%. At the RP2D of 10 mg/kg, pacmilimab displayed a favorable tolerability profile. Grade 3 or higher treatment-related adverse events were reported in 10 patients and serious TRAEs in six patients. The discontinuation rate due to TRAEs was a low 2%. Grade 3 or higher irAEs occurred in two patients, one each for rash and myocarditis. "First-in-human Study of Pacmilimab in Combination with Ipilimumab in Advanced Solid Tumors Published in the Journal for ImmunoTherapy of Cancer." The goal of this first-in-human dose-finding study was to evaluate the tolerability and preliminary antitumor activity of pacmilimab combined with ipilimumab in patients with advanced, unresectable solid tumors. Twenty-seven patients who had not been previously treated with an ICI were enrolled. The ORR was 19%, including one patient with anal squamous cell carcinoma having a complete response and four partial responses in patients with leiomyosarcoma, mesothelioma, testicular cancer, and cancer of unknown primary. Moreover, these responses appeared durable, with four of five responses lasting for more than 1 year as of data cutoff on August 28, 2020, including the patient with a complete response maintaining for more than 24 months.

ShowHide Related Items >><<
CTMX CytomX Therapeutics
$5.73 /

+0.15 (+2.69%)

CTMX CytomX Therapeutics
$5.73 /

+0.15 (+2.69%)

05/28/21 Barclays
CytomX Therapeutics downgraded to Underweight from Equal Weight at Barclays
03/29/21
Fly Intel: Top five analyst initiations
03/29/21 JPMorgan
CytomX Therapeutics initiated with an Overweight at JPMorgan
03/23/21 Jefferies
CytomX Therapeutics upgraded to Buy from Hold at Jefferies
CTMX CytomX Therapeutics
$5.73 /

+0.15 (+2.69%)

  • 21
    Jan
Hot Stocks
CytomX Therapeutics announces publication of data for CX-2029 » 08:29
06/21/21
06/21
08:29
06/21/21
08:29
CTMX

CytomX Therapeutics

$7.17 /

-0.01 (-0.14%)

, ABBV

AbbVie

$113.10 /

-1.785 (-1.55%)

CytomX Therapeutics…

CytomX Therapeutics (CTMX) announced that results from its Phase 1 first-in-human study of CX-2029 in patients with advanced solid tumors were published online in the peer-reviewed journal Clinical Cancer Research. This study showed that CX-2029, currently being co-developed by CytomX and AbbVie (ABBV), was generally well-tolerated and can elicit anti-tumor responses in certain patients. CD71 is a cell surface protein essential for iron uptake in dividing cells and is highly expressed in a number of solid and hematologic cancers. However, given its central role in iron metabolism, CD71 is present on most healthy cells and has been, until now, undruggable with conventional ADCs. CX-2029 is designed to be activated in the tumor microenvironment by tumor-associated proteases, thereby limiting off-tumor toxicity and creating a therapeutic window for CD71. The goal of this Phase 1 dose-escalation, multicenter study was to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of CX-2029. A total of 45 patients were enrolled to receive CX-2029 intravenously every three weeks at dose levels ranging from 0.1 mg/kg to 5 mg/kg. Encouraging preliminary clinical activity was observed at doses of 2 mg/kg and higher. Notably, three of four patients with squamous non-small cell lung carcinoma had stable disease or better, including two confirmed partial responses; and seven of eight patients with head and neck squamous cell carcinoma had SD or better, including one confirmed PR at 3 mg/kg and one prolonged SD ongoing at approximately 25 weeks, as of the reported August 2020 data cutoff. Despite having received a median of three prior lines of cancer regimens, these heavily-pretreated patients generally tolerated CX-2029 well. The most common dose-dependent adverse events were anemia and neutropenia, toxicities commonly associated with the payload of this ADC. Based on several safety parameters, including no cycle 1 DLTs, no discontinuations due to toxicity, and a long-term tolerability that appeared to be acceptable for chronic administration with supportive care for anemia, 3 mg/kg every 3 weeks was declared the recommended Phase 2 dose. The ongoing Phase 2 expansion study is evaluating CX-2029 as monotherapy in four cohorts: squamous NSCLC, HNSCC, esophageal and gastroesophageal junction cancers, and diffuse large B-cell lymphoma. Initial results are expected in the fourth quarter of 2021.

ShowHide Related Items >><<
CTMX CytomX Therapeutics
$7.17 /

-0.01 (-0.14%)

ABBV AbbVie
$113.10 /

-1.785 (-1.55%)

CTMX CytomX Therapeutics
$7.17 /

-0.01 (-0.14%)

05/28/21 Barclays
CytomX Therapeutics downgraded to Underweight from Equal Weight at Barclays
03/29/21
Fly Intel: Top five analyst initiations
03/29/21 JPMorgan
CytomX Therapeutics initiated with an Overweight at JPMorgan
03/23/21 Jefferies
CytomX Therapeutics upgraded to Buy from Hold at Jefferies
ABBV AbbVie
$113.10 /

-1.785 (-1.55%)

05/19/21 Piper Sandler
Piper 'incrementally bullish' on Biohaven, AbbVie migraine drugs
05/13/21 Cantor Fitzgerald
Soliton downgraded to Neutral from Overweight at Cantor Fitzgerald
05/11/21 Maxim
Soliton downgraded to Hold from Buy at Maxim
05/03/21 Mizuho
AbbVie price target raised to $128 from $126 at Mizuho
CTMX CytomX Therapeutics
$7.17 /

-0.01 (-0.14%)

ABBV AbbVie
$113.10 /

-1.785 (-1.55%)

  • 21
    Jan
ABBV AbbVie
$113.10 /

-1.785 (-1.55%)

CTMX CytomX Therapeutics
$7.17 /

-0.01 (-0.14%)

ABBV AbbVie
$113.10 /

-1.785 (-1.55%)

ABBV AbbVie
$113.10 /

-1.785 (-1.55%)

Over a quarter ago
Downgrade
CytomX Therapeutics downgraded to Underweight from Equal Weight at Barclays » 05:58
05/28/21
05/28
05:58
05/28/21
05:58
CTMX

CytomX Therapeutics

$8.19 /

-0.01 (-0.12%)

Barclays analyst Peter…

Barclays analyst Peter Lawson downgraded CytomX Therapeutics to Underweight from Equal Weight with a price target of $7, down from $9. The analyst wants greater confidence around the next data updates and says he needs to see further data to be more constructive on the shares.

ShowHide Related Items >><<
CTMX CytomX Therapeutics
$8.19 /

-0.01 (-0.12%)

CTMX CytomX Therapeutics
$8.19 /

-0.01 (-0.12%)

03/29/21
Fly Intel: Top five analyst initiations
03/29/21 JPMorgan
CytomX Therapeutics initiated with an Overweight at JPMorgan
03/23/21 Jefferies
CytomX Therapeutics upgraded to Buy from Hold at Jefferies
09/22/20 Guggenheim
Guggenheim taking more conservative view, downgrades CytomX to Neutral
CTMX CytomX Therapeutics
$8.19 /

-0.01 (-0.12%)

  • 21
    Jan
CTMX CytomX Therapeutics
$8.19 /

-0.01 (-0.12%)

Earnings
CytomX Therapeutics reports Q1 EPS (26c), consensus (35c) » 17:35
05/06/21
05/06
17:35
05/06/21
17:35
CTMX

CytomX Therapeutics

$8.16 /

-0.36 (-4.23%)

Reports Q1 revenue $16M,…

Reports Q1 revenue $16M, consensus $15.43M. "Building on the sustained and focused performance by the CytomX team throughout 2020, we made excellent progress in the first quarter of 2021 with an ongoing emphasis on our two lead clinical product candidates, praluzatamab ravtansine (CX-2009) and CX-2029, both of which are in key Phase 2 studies addressing late-stage cancers with substantial unmet need," said Sean McCarthy, D.Phil., president, chief executive officer and chairman of CytomX Therapeutics. "We also continued to innovate with the unveiling of our work on conditionally activated cytokines that leverages the depth of our expertise in protein engineering, protease biology, and our understanding of the tumor microenvironment. Our leadership in the field of conditional activation and the versatility of our Probody technology platform position us for success in realizing our vision of transforming lives with safer, more effective therapies," added Dr. McCarthy.

ShowHide Related Items >><<
CTMX CytomX Therapeutics
$8.16 /

-0.36 (-4.23%)

CTMX CytomX Therapeutics
$8.16 /

-0.36 (-4.23%)

03/29/21
Fly Intel: Top five analyst initiations
03/29/21 JPMorgan
CytomX Therapeutics initiated with an Overweight at JPMorgan
03/23/21 Jefferies
CytomX Therapeutics upgraded to Buy from Hold at Jefferies
09/22/20 Guggenheim
Guggenheim taking more conservative view, downgrades CytomX to Neutral
CTMX CytomX Therapeutics
$8.16 /

-0.36 (-4.23%)

  • 21
    Jan
CTMX CytomX Therapeutics
$8.16 /

-0.36 (-4.23%)

Earnings
CytomX Therapeutics reports Q1 EPS (26c), consensus (35c) » 17:35
05/06/21
05/06
17:35
05/06/21
17:35
CTMX

CytomX Therapeutics

$8.16 /

-0.36 (-4.23%)

Reports Q1 revenue $16M,…

Reports Q1 revenue $16M, consensus $15.43M. "Building on the sustained and focused performance by the CytomX team throughout 2020, we made excellent progress in the first quarter of 2021 with an ongoing emphasis on our two lead clinical product candidates, praluzatamab ravtansine (CX-2009) and CX-2029, both of which are in key Phase 2 studies addressing late-stage cancers with substantial unmet need," said Sean McCarthy, D.Phil., president, chief executive officer and chairman of CytomX Therapeutics. "We also continued to innovate with the unveiling of our work on conditionally activated cytokines that leverages the depth of our expertise in protein engineering, protease biology, and our understanding of the tumor microenvironment. Our leadership in the field of conditional activation and the versatility of our Probody technology platform position us for success in realizing our vision of transforming lives with safer, more effective therapies," added Dr. McCarthy.

ShowHide Related Items >><<
CTMX CytomX Therapeutics
$8.16 /

-0.36 (-4.23%)

CTMX CytomX Therapeutics
$8.16 /

-0.36 (-4.23%)

03/29/21
Fly Intel: Top five analyst initiations
03/29/21 JPMorgan
CytomX Therapeutics initiated with an Overweight at JPMorgan
03/23/21 Jefferies
CytomX Therapeutics upgraded to Buy from Hold at Jefferies
09/22/20 Guggenheim
Guggenheim taking more conservative view, downgrades CytomX to Neutral
CTMX CytomX Therapeutics
$8.16 /

-0.36 (-4.23%)

  • 21
    Jan
CTMX CytomX Therapeutics
$8.16 /

-0.36 (-4.23%)

Conference/Events
CytomX Therapeutics to host conference call » 12:55
04/07/21
04/07
12:55
04/07/21
12:55
CTMX

CytomX Therapeutics

$7.79 /

-0.39 (-4.77%)

Management discusses the…

Management discusses the Company's Probody technology platform and the two conditionally activated ADCs, praluzatamab ravtansine (CX-2009) and CX-2029 on a conference call to be held on April 7 at 1 pm. Webcast Link

ShowHide Related Items >><<
CTMX CytomX Therapeutics
$7.79 /

-0.39 (-4.77%)

CTMX CytomX Therapeutics
$7.79 /

-0.39 (-4.77%)

03/29/21
Fly Intel: Top five analyst initiations
03/29/21 JPMorgan
CytomX Therapeutics initiated with an Overweight at JPMorgan
03/23/21 Jefferies
CytomX Therapeutics upgraded to Buy from Hold at Jefferies
09/22/20 Guggenheim
Guggenheim taking more conservative view, downgrades CytomX to Neutral
CTMX CytomX Therapeutics
$7.79 /

-0.39 (-4.77%)

  • 21
    Jan
CTMX CytomX Therapeutics
$7.79 /

-0.39 (-4.77%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.